Bermekimab
Bermekimab
Bermekimab (pronounced: bur-meh-kim-ab) is a monoclonal antibody designed for the treatment of inflammatory diseases, cancer, and other medical conditions.
Etymology
The name "Bermekimab" is derived from the standard nomenclature for therapeutic monoclonal antibodies, where "-mab" is used as a suffix for monoclonal antibodies. The prefix "Ber-" is an arbitrary sequence and does not have a specific meaning.
Usage
Bermekimab is used in the treatment of various diseases including, but not limited to, cancer, hidradenitis suppurativa, and non-alcoholic steatohepatitis (NASH). It works by targeting and neutralizing interleukin-1 alpha (IL-1α), a protein that plays a key role in the inflammation and growth of certain diseases.
Related Terms
- Monoclonal Antibodies: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Interleukin-1 alpha: A type of protein that in humans is encoded by the IL1A gene. It is involved in various immune responses, inflammatory processes, and hematopoiesis.
- Hidradenitis suppurativa: A skin condition that causes small, painful lumps to form under the skin. The lumps can break open, or tunnels can form under the skin. The condition mostly affects areas where the skin rubs together, such as the armpits, groin, buttocks, and breasts.
- Non-alcoholic steatohepatitis: A type of fatty liver disease, characterized by inflammation and accumulation of fat in the liver. It is not related to alcohol consumption.
External links
- Medical encyclopedia article on Bermekimab
- Wikipedia's article - Bermekimab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski